Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from…
Cambridge, Massachusetts-based Mersana Therapeutics Inc, a provider of Fleximer antibody-drug conjugate technology, has secured $35 million in Series B-1 financing.…